Andreas and Thomas Strüngmann (via Agreus Group)
Billionaire BioNTech backers have been kicking the tires at Novartis' big generics arm — report
While the ultimate fate of Novartis’ big generics arm Sandoz may still be up in the air, there’s no doubt it’s in play as a …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
